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Summary 
 
 
  
 
AB-PINACA (N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide), 
originally developed by Pfizer Inc. as a synthetic cannabinoid receptor agonist (SCRA), has been 
encountered outside medical settings as a synthetic constituent and found in herbal smoking 
mixtures that are sold under a variety of brand names. It is common for retailers to purchase bulk 
quantities of the synthetic substance and add the synthetic material to plant matter that is then 
distributed onto the market. However, AB-PINACA is also available in powdered form as a 
“research chemical”. The identification of AB-PINACA was reported first in 2012 by Japan and 
more forensic detections began to emerge in other countries in 2013. Data from law enforcement 
suggest that AB-PINACA was one of the most prevalent substances in the United States of 
America in 2014, which dropped again in the following years.  A small number of in vitro and in 
vivo studies are currently available but the data indicate that AB-PINACA binds to and activates 
human CB1 and CB2 receptors at low nanomolar concentrations, and that it induces a number of 
biological responses also triggered by the naturally occurring phytocannabinoid Δ9-THC. In tetrad 
assays (locomotor suppression, antinociception, hypothermia, and catalepsy), for example, AB-
PINACA was shown to be 2- to 14-fold more potent than Δ9-THC and the effects were 
rimonabant-reversible. In some in vitro assays, AB-PINACA acted as a full agonist with slight 
selectivity for the hCB2 receptor. AB-PINACA also fully substituted for Δ9-THC in the drug 
discrimination paradigm and was 1.5-fold more potent than the training drug, which suggests that 
AB-PINACA may have abuse liability similar to Δ9-THC and/or other internationally controlled 
synthetic cannabinoid receptor agonists.   
 
Reports indicate an increasing trend for SCRAs being implicated in mini epidemics that have been 
associated with severe adverse drug effects including deaths. Reported adverse drug reactions 
associated with a range of SCRAs frequently include gastrointestinal (e.g. nausea/hyperemesis), 
neurological (e.g. hallucination, agitation, anxiety, paranoia, confusion, delusions, catatonia, 
lethargy, psychosis (including susceptible individuals)), cardiovascular (e.g. tachycardia, 
hypertension) and renal (e.g. acute kidney failure) features. The total number of cases reported in 
the scientific literature that make a causal link with AB-PINACA is very small. Intoxications and 
deaths associated with AB-PINACA have been reported but very few details are available. 
‘Driving Under the Influence’ cases linked to AB-PINACA intoxication and ‘Drug Recognition 
Expert’ exams revealed significant impairment.  Although not specific to just AB-PINACA, there 
are indications that socially vulnerable and stigmatized drug users for example found in homeless 
and prison populations, are increasingly associated with problematic use of SCRA products. 
Heavy use of SCRAs has been associated with problematic withdrawal symptoms even though 
further research is needed to investigate the underlying mechanisms. Epidemiological data, such as 
prevalence of use, abuse and dependence information specifically related to AB-PINACA could 
not be identified.  
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1.   Substance identification  
A. International Nonproprietary Name (INN) 
Not available. 
B. Chemical Abstract Service (CAS) Registry Number 
1445752-09-9 ((S)-free base) 
 1445583-20-9 (free base) 
C. Other Chemical Names 
N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;  
(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide; 
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentylindazole-3-carboxamide 
D. Trade Names 
Not available. 
E. Street Names 
AB-PINACA 
F. Physical Appearance 
The hydrochloride salt has been described as a white powder.1  
G. WHO Review History 
AB-PINACA has not been previously pre-reviewed or critically reviewed. A direct 
critical review is proposed based on information brought to WHO’s attention that 
AB-PINACA is clandestinely manufactured, of especially serious risk to public 
health and society, and of no recognized therapeutic use by any party. Preliminary 
data collected from literature and different countries indicated that this substance 
may cause substantial harm and that it has no medical use. 
 
2. Chemistry 
A. Chemical Name 
IUPAC Name: N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-
indazole-3-carboxamide 
CA Index Name: N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-pentyl-
1H-indazole-3-carboxamide 
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B. Chemical Structure 
Free base: 
 
Molecular Formula: C18H26N4O2 
Molecular Weight: 330.43 g/mol 
  
C. Stereoisomers 
The synthesis procedures described in the original patent literature2 place an 
emphasis on the preparation of the (S)-enantiomer based on the use of L-valinamide 
in the last reaction step (see below). However, it is currently not known whether 
AB-PINACA has been exclusively found on the market with the absolute (S)- 
configuration although it appears very likely to be the case.  
D. Methods and Ease of Illicit Manufacturing 
The preparation of AB-PINACA is straightforward and follows standard procedures 
that start with indazole-3-carboxylic acid (1), which can also be prepared if not 
available as the starting material. Esterification (2) and N1-alkylation (3) followed 
by saponification provides access to the carboxylic acid precursor (4) that is then 
coupled with L-valinamide to give the (S)-enantiomer of AB-PINACA (5).2, 3 It was 
also observed that the alkylation reaction resulted in the formation of the N2-
alkylated regioisomer as an impurity, which was then shown to result in very low 
potency as CB1 and CB2 receptor agonists.
3, 4 
 
 
 
(a) Concentrated H2SO4, MeOH, reflux, 4 h; (b) 1-bromopentane, t-BuOK, THF, 0 °C to rt, 48 h, (c) NaOH, 
MeOH, rt, 24 h; (d) EDC HCl, HOBt, DIPEA, L-valinamide, DMF, rt, 24 h.3, 4 The two nitrogen atoms found 
in the indazole ring of AB-PINACA (5) have been numbered indicate the site of alkylation. The 2H- 
regioisomer of (5) has been detected as a synthesis impurity.3, 4 
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E. Chemical Properties 
Melting point: 121.8 °C (base).1 
Boiling point: Information could not be identified. 
Solubility: Information could not be identified. AB-PINACA is expected to be 
lipophilic in nature and therefore soluble in organic solvents. 
F. Identification and Analysis  
Chemical and analytical data are available. AB-PINACA has also been employed 
for analytical purposes and featured in a range of routine methods of analysis 
associated with forensic and clinical investigations (Annex 2). The analytical 
determination of synthetic cannabinoid receptor agonists such as AP-PINACA in 
biological fluids can be a challenge, for example in cases where analytical 
methodologies are not specifically designed to detect these substances. In some 
instances (e.g. analysis of urine), the detection of metabolites may be the preferred 
approach. Since the synthesis of AB-PINACA has been reported to produce the 2H- 
regioisomer,3, 4 it is conceivable that it might be detectable in drug products 
available on the market. In this case, the analytical differentiation between these 
isomers is needed. The explicit identification of the (S)-enantiomer has not been 
confirmed in the reports associated with the identification of AB-PINACA. 
However, given that the original patent literature makes explicit reference to the 
evaluation of (S)-enantiomers2 and that L-valinamide is cheap and widely available, 
it would seem likely that the AB-PINACA available on the market exists as the (S)-
enantiomer. Until further information is available, one cannot exclude the existence 
of the (R)-enantiomer and the differentiation between the two might present 
challenges in routine forensic laboratories. An overview of brand names linked to 
the presence to AB-PINACA has been published for selected examples reported by 
the Customs and Border Protection Laboratory in the United States of America 
(period December 2013-September 2014).5 However, it is worth noting that product 
compositions constantly change, which means that identical product names might 
not contain identical constituents at different time points. 
 
3. Ease of Convertibility Into Controlled Substances 
Information could not be identified. 
 
4. General Pharmacology 
A. Routes of administration and dosage 
AB-PINACA, in its pure form but mostly as a synthetic constituent added to a plant 
matrix (e.g. damiana (Turnera diffusa) or marshmallow (Althaea officinalis), is 
normally smoked but reliable data about dosage are normally unavailable. The 
variations in drug composition and quantities frequently observed with many 
smoking mixtures (e.g.6) make such estimation impossible for users despite of 
information may be displayed on a product label.  
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B.  Pharmacokinetics 
Information from clinical studies in humans is not available. A number of reports 
have been published that describe the biotransformation (and/or metabolic stability) 
of AB-PINACA under in vitro conditions, either using human liver microsomes,7-10 
human hepatocytes9, 10 or recombinant human carboxylesterases.8 The analysis of 
urine samples obtained from a drug administration study in mice11 and one 
involving authentic human specimen9 has also been published. Metabolites 
identified following incubation with human liver microsomes included the amide 
hydrolysis product AB-PINACA-COOH species hydroxylated at the N-pentyl chain 
and butanamide moiety and the indazole ring. Hydroxylations were identified both 
at AB-PINACA and AB-PINACA-COOH.7, 8 Furthermore, the inhibition of 
carboxylesterases 1 and 2 (CES) active in both human liver and pulmonary 
microsomes showed that the AB-PINACA hydrolysis was abolished when using the 
CES 1 inhibitor benzyl (at 100 μM) whereas only a 20% reduction was noticed 
using the selective CES 2 inhibitor loperamide.8   
 
A metabolic stability study carried out with human liver microsomes suggested an 
in vitro half-life (T1/2) of 18.7 ± 0.4 min and an in vitro microsomal intrinsic 
clearance (CLint, micr) of 0.037 mL/min/mg. Scaled to whole-liver dimensions, the 
intrinsic clearance of AB-PINACA was estimated at 35 mL/min/kg. The calculated 
predicted hepatic clearance (CLH) (without considering plasma protein binding and 
using a simplified Rowland’s equation) was 12.7 mL/min/kg and the extraction 
ratio was determined as 0.6.9 
 
An incubation study with human hepatocytes revealed the detection of 23 AB-
PINACA metabolites (phase I and phase II) that reflected carboxamide hydrolysis, 
hydroxylation, ketone formation, carboxylation, epoxide formation with subsequent 
hydrolysis, or reaction combinations. Major metabolites included AB-PINACA-
COOH, carbonyl-AB-PINACA (ketone function on N-pentyl chain), and 
hydroxypentyl AB-PINACA. Nine metabolites represented second-generation 
metabolites derived from AB-PINACA-COOH. A comparison with authentic 
human urine samples indicated that the most intense urinary metabolites (signal 
response under electrospray ionization conditions) reflected amide hydrolysis, 
additional oxidation, and often glucuronidation. Four of the five major metabolites 
identified in the hepatocyte assay were among the top 20 most intense metabolites 
in the urine specimens.9 AB-PINACA-COOH was also detected in another urine 
sample collected from a user.12 Incubation experiments with various human liver 
preparations (primary human hepatocytes, pooled human S9 fraction, pooled human 
liver microsomes combined with cytosol) uncovered extensive metabolism. A 
metabolite common to all samples was AB-PINACA-COOH. Two additional main 
species detected in an authentic human urine sample represented amide hydrolysis 
plus ketone formation and amide hydrolysis plus oxidation.10  
The analysis of mouse urine samples following AB-PINACA administration 
revealed the detection of monohydroxylated metabolites and their glucuronides.11 
“AB-PINACA N-pentanoic acid” was reported as a metabolite detected in serum 
and urine of a 10 month old female who ingested a “K2” cigarette 
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unintentionally.13, 14  
C. Pharmacodynamics 
A number of in vitro and in vivo studies have been carried out which suggest that 
AB-PINACA, a synthetic cannabinoid receptor agonist (SCRA), binds to and 
activates CB1 and CB2 receptors, and that it induces a number of biological 
responses that are also triggered by the naturally occurring phytocannabinoid Δ9-
THC and other internationally controlled SCAs (Tables 1 and 2).  
 
In vitro data – functional activity: 
 
AB-PINACA was more potent than Δ9-THC in the ability to activate G-protein-
gated inwardly rectifying K+ channels (GIRKs) in mouse AtT20 neuroblastoma 
cells transfected with human CB1 and CB1 receptors. AB-PINACA was 20 times 
(hCB1) and 5.2 times (hCB2) more potent than CP-55,490 and showed similar 
efficacy as a full agonist. In comparison to Δ9-THC, AB-PINACA was ca. 143 
times more potent. As a partial agonist, Δ9-THC elicited 58% activation (hCB1) 
compared to a 32% efficacy (hCB2) that could only be achieved at a concentration 
of 30 μM. In this assay, AB-PINACA was 15 times (hCB1) and 8.8 (hCB2) times 
more potent than the full agonist JWH-018 whereas efficacy was slightly lower at 
hCB1 and higher at hCB2 (Table 1).
3 When using the [35S]GTPγS turnover assay, it 
was reported that AB-PINACA acted as an agonist at both CB receptors. Although 
it was less potent than CP-55,940, an augmented efficacy was observed for AB-
PINACA at  hCB1.
11 Agonist-mediated inhibition of forskolin stimulated cAMP 
levels monitored in HEK-293 cells expressing the hCB1 receptor and compared 
relative to WIN-55,212-2, AP-PINACA was determined to be a full agonist 
together with the SCRAs JWH-018 and XLR-11 whereas CP-55,940 and HU-210 
were identified as partial agonists. Under these assay conditions, JWH-073 was 
inactive (Table 1).15 From the perspective of evaluating living cellular functional 
responses to drug administration, hCB1-induced suppression of Ca
2+ spiking was 
investigated in cultured rat hippocampal neurons (fluorescence detection and multi-
electrode experiments). AP-PINACA induced significant overall suppression of 
Ca2+ spiking together with other SCRAs. HU-210 did not produce a suppression 
using the same concentration.15 In multi-electrode experiments, AB-PINACA 
caused significant suppression overall at both 10 μM and 1 μM but not at all 
investigated time points.16  
 
In vitro data – receptor binding: 
 
Receptor binding studies in HEK-293 cells transfected with hCB1 and hCB2 
receptors using the radioligand [3H]CP-55,940 confirmed that AB-PINACA showed 
nanomolar affinity to both receptors with a 3.3-fold selectivity toward hCB2. In 
comparison, CP-55,940 showed a 2-fold selectivity toward hCB2 but with higher 
affinity than AB-PINACA at both receptors.11 AB-PINACA also displayed a 23- 
and 41-fold higher affinity to hCB1 and hCB2 than Δ9-THC (Table 1).17  
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Table 1. AB-PINACA in-vitro data  Ref 
 
Functional activity: a 
AB-PINACA at hCB1: EC50 = 1.2 nM (Emax = 103%); hCB2: EC50 = 2.5 nM (Emax = 104%) 
Δ9-THC at hCB1: EC50 = 172 nM (Emax = 58%); hCB2: EC50 not determined; too low (Emax = 32% at 30,000 nM) 
CP-55,490 at hCB1: EC50 = 24 nM (Emax = 100%); hCB2: EC50 = 13 nM (Emax = 100%) 
JWH-018 at hCB1: EC50 = 18 nM (Emax = 116%); hCB2: EC50 = 22 nM (Emax = 87%) 
 
Banister et al.3 
 
Receptor binding:  
Details not reported 
CB1: Ki = 2.64 nM ; 0.93 nM 
 
Functional activity:   
No details reported 
EC50 = 14.3 nM 
 
DEA5 
 
Receptor binding: b 
 
AB-PINACA at hCB1: Ki = 2.87 nM ([3H]CP-55,940); hCB2: Ki = 0.88 nM ([3H]CP-55,940).  
CP-55,940 at hCB1: Ki = 0.59 nM ([3H]CP-55,940); hCB2: Ki = 0.30 nM ([3H]CP-55,940).  
Δ9-THC (data from previous study) at hCB1: Ki = 67 nM ([3H]CP-55,940); hCB2: Ki = 36 nM ([3H]CP-55,940).17  
XLR-11 (data from previous study) at hCB1: Ki = 24 nM ([3H]CP-55,940); hCB2: Ki = 2.1 nM ([3H]CP-55,940).17  
UR-144 (data from previous study) at hCB1: Ki = 29 nM ([3H]CP-55,940); hCB2: Ki = 4.5 nM ([3H]CP-55,940).17  
 
[35S]GTPγS turnover: c 
 
AB-PINACA at hCB1: EC50 = 71 nM (Emax = 192%); hCB2: EC50 = 14.9 nM (Emax = 41%). 
CP-55,940 at hCB1: EC50 = 23.3 nM (Emax = 124%); hCB2: EC50 = 2.1 nM (23 nM in ref17) (Emax = 63%). 
XLR-11 (data from previous study) at hCB1: ED50 = 159 nM (“full agonist”); hCB2: ED50 = 145 nM (“full agonist”).17 
UR-144 (data from previous study) at hCB1: ED50 = 98 nM (“full agonist”); hCB2: ED50 = 334 nM (“full agonist”).17 
 
Wiley et al.11  
 
Functional activity (hCB1): d  
 
Inhibition of forskolin stimulated cAMP levels:  
Efficacy relative to WIN-55,212-2: EC50 = 79 nM (Emax = 65%). 
 
AB-PINACA: EC50 = 79 nM (Emax = 69%), full agonist.  
CP-55,940: EC50 = 316 nM (Emax = 47%), partial agonist.  
HU-210: EC50 = 1585 nM (Emax = 35%), partial agonist.  
JWH-018: EC50 = 251 nM (Emax = 55%), full agonist.  
JWH-073: no activity. 
XLR-11: EC50 = 3981 nM (Emax = 65%), full agonist.  
5F-PB-22: EC50 = 39.8 nM (Emax = 67%), full agonist.  
 
hCB1-induced suppression of Ca2+ spiking in cultured rat hippocampal neurons: 
Compared to addition of blank. 
 
AB-PINACA: significant suppression of Ca2+ spiking at 10 μM. 
WIN-55,212-2: significant suppression at 10 μM. 
CP-55,940: significant suppression at 10 μM. 
HU-210: no suppression at 10 μM. 
XLR-11: significant suppression at 1 μM and10 μM (significant more suppression than AB-PINACA) 
5F-PB-22: significant suppression at 10 μM. 
 
Costain et al.15  
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In vivo data: 
 
Currently available data suggest that AB-PINACA induces responses in animals 
that are also seen with Δ9-THC and other SCRAs, such as suppression of locomotor 
activity, decreased body temperature, antinociception, and catalepsy (tetrad assays). 
For example, in the tetrad assays, AB-PINACA was 2- to 14-fold more potent than 
Δ9-THC. In addition, these effects were rimonabant reversible.11 Furthermore, AB-
PINACA was found to fully substitute for Δ9-THC using the drug discrimination 
paradigm in mice (nose poke response) although this was only achieved at a 3 
mg/kg and accompanied by substantial decreases in response rate, with only a small 
percentage of mice responding (Table 2). Another documented difference to Δ9-
 
Functional activity (hCB1): e  
 
hCB1-induced suppression of Ca2+ spiking in cultured rat hippocampal neurons (multi-electrode experiments): 
Percent change in number of spontaneous spikes before and after addition of 0.1% DMSO. 
 
AB-PINACA caused suppression overall at both 10 μM and 1 μM but not at all investigated time points. 
WIN-55,212-2 (10 μM), WIN-55,212-3 (10 μM), HU-210 (10 μM), CP-55,940 (10 μM) suppressed overall activity. 
JWH-018 (10 μM and 1 μM), XLR-11 (10 μM), JWH-250 (10 μM), 5F-PB-22 (10 μM), and MAM-2201 (10 μM and 
1 μM) suppressed overall activity. 
 
“Overall“ suppression determined at the end of the recording time. For some compounds, suppression was not always 
considered significant at a number of earlier time points, thus, indicating suppression occurring at longer incubation 
times.   
 
Rimonabant (5 μM) significantly reversed 5F-PB-22-induced suppression (10 μM) (AB-PINACA was not tested) at 
the first three time-matched recordings and overall. 
Tauskela et al.16 
 
a Ref3: hCB1 and hCB2 receptors in stably transfected mouse AtT20 neuroblastoma cells; FLIPR membrane potential assay (blue) used for 
quantitative determination of K+ flux (hyperpolarization) linked to G-protein activation: G-protein-gated inwardly rectifying K+ channels 
(GIRKs); plates were incubated at ambient CO2 for 45 min at 37 °C; receptor activation and stimulation of cellular hyperpolarization led 
to decrease in fluorescence response. Comparison of test drugs was normalized against CP-55,940 response (set at 100% efficacy).  
 
b Ref11: hCB1 and hCB2 (HEK-293); [3H]CP-55,940 (0.62 nM) used for displacement (nonspecific binding determined by inclusion of 10 
μM unlabeled CP-55,940).   
 
c Ref11: incubation of mixture containing test drug (0.25 nM to 20 μM), GDP (20 μM), GTPγ[35S] (100 pM), and hCB1 and hCB2 
membrane preparations from HEK-293 cells. Basal binding determined in the absence of test drug; Emax values represent percentage of 
maximal increase for [35S]GTPγS binding over basal. 
 
d Ref15: GloSensor™ cAMP assay; agonist-mediated inhibition of forskolin-stimulated cyclic adenosine monophosphate (cAMP) levels 
was monitored in live HEK293T cells transfected with human cannabinoid receptor 1 gene (CNR1) and pGloSensor-22F; efficacy 
determinations (%inhibition) relative to full agonist WIN-55,212-2. Synthetic cannabinoids were added 12 min prior to the addition of 10 
μM forskolin. Luminescence was determined 15 min after forskolin addition; data were normalized to vehicle readings.  Low-density 
primary hippocampal neuron cultures were loaded with a Ca2+ indicator and exposed to low Mg2+ buffer to induce spontaneous, transient 
increases in intracellular Ca2+ levels (Ca2+ spikes). Post-drug frequencies were normalized to pre-drug frequencies and post-drug % 
inhibition was calculated relative to the pre-drug condition.  
 
e Ref16: Hippocampal neurons plated at high density; each multi-electrode array served as its own internal control: two 20 min baseline 
recordings were performed prior to acquiring four 20 min recordings with a cannabinoid or DMSO vehicle present; online extracellular 
spike detection was used; activity was monitored over a total 80 min exposure of a cannabinoid, in 20 min recording sessions.  
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THC was the observation of short-lived convulsive behavior.11 In one study, 
rimonabant was observed to partially reverse hypothermic effects in male Wistar 
rats whereas administration of a CB2 receptor antagonist was considered 
ineffective.3 A number of acute and long-lasting (residual) behavioral and 
neurochemical effects were investigated in adolescent rats following AB-PINACA 
and Δ9-THC administration (low dose and high dosing regimen), which resulted in 
somewhat comparable observations (Table 2). Acute effects observed were 
reduction in locomotor activity, inhibition of weight gain, and increased anxiety-
like behaviors. The assessment of residual effects revealed that Δ9-THC but not 
AB-PINACA was associated with impairment of social interaction, whereas 
recognition memory impairment was observed for both drugs (2 weeks).18 
Microdialysis studies (nucleus accumbens) in male Sprague–Dawley rats revealed 
weak fluctuating changes in dopamine and serotonin levels where statistical 
significance was only reached at individual time points, mostly below the 200% 
level (Table 2).19  
 
 
Table 2. In vivo assay data for AB-PINACA 
Behavior / physiology / neurochemistry Ref 
Body temperature: a 
AB-PINACA:  hypothermic effect (0.3–3 mg/kg) (> 1.5 °C) was observed. Maximum drop in 
body temperature observed with in the first hour of the 6 h monitoring period.   
 
Rimonabant partially reversed hypothermic effects but CB2 receptor antagonist SR-144528 had 
only negligible effects on drug-induced hypothermia.  
 
Heart rate: a 
AB-PINACA: significant decrease in heart rate but more variable than body temperature data, 
possibly reflecting multiple determinants.  
 
Rimonabant reduced AB-PINACA-induced bradycardia but without reaching statistical 
significance. SR-144528 pre-treatment did not have any effects.  
 
Banister et al.3 
Tetrad tests: b 
 
Inhibition of spontaneous activity (locomotor activity): 
AB-PNACA: ED50 = 7.6 μmol/kg 
Δ9-THC: ED50 ED50 = 104 μmol/kg 
 
Drop in total counts compared to vehicle condition with significant difference: 
AB-PINACA: 10 and 30 mg/kg 
Δ9-THC: not reached with dose up to 56 mg/kg 
 
Percent maximum possible antinociceptive effect (tail-flick): 
AB-PINACA: ED50 = 13.7 μmol/kg 
Δ9-THC: ED50 = 34 μmol/kg 
 
Compared to vehicle condition with significant difference: 
AB-PINACA: 10 and 30 mg/kg 
Δ9-THC: 56 mg/kg 
 
Rectal temperature (hypothermia): 
AB-PINACA: ED50 = 5.3 μmol/kg 
Δ9-THC: ED50 = 30 μmol/kg 
Wiley et al.11  
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Drop in rectal temperature compared to vehicle condition with significant difference: 
AB-PINACA: 3, 10 and 30 mg/kg 
Δ9-THC: 10 and 56 mg/kg 
 
Ring immobility (catalepsy): 
AB-PINACA: ED50 = 13.9 μmol/kg 
Δ9-THC: ED50 = 30 μmol/kg 
 
Percentage increase in immobility compared to vehicle condition with significant difference: 
AB-PINACA: 3, 10 and 30 mg/kg 
Δ9-THC: 3, 10 and 56 mg/kg 
 
Intraperitoneal doses of 56 mg/kg Δ9-THC and 30 mg/kg AB-PINACA (injected 10 min prior to 
test drug) significantly suppressed locomotor activity and produced antinociception, hypothermia 
and catalepsy, which were attenuated by co-administration of 3 mg/kg (i.p.) rimonabant. 
 
In addition to effects on tetrad assays, 30 mg/kg AB-PINACA induced convulsions, flattened body 
posture (splayed limbs), and labored breathing in most mice within 1 minute after i.p. injection. 
Mice started to recover by the end of tetrad testing. 
 
Drug discrimination (lever and nose poke response): c 
AB-PINACA: ED50 not reported (lever); ED50 = 3.78 μmol/kg (nose poke) 
Δ9-THC: ED50 = 4.5 μmol/kg (lever); ED50 = 5.7 μmol/kg (nose poke) 
AB-CHMINACA: ED50 not reported (lever); ED50 = 0.34 μmol/kg (nose poke) 
 
AB-PINACA substituted fully and dose-dependently for Δ9-THC, but full substitution was 
achieved only at a dose (3 mg/kg) that was accompanied by substantial decreases in response rate, 
with only a small percentage (22%) of mice responding at this dose. It was suggested that the 
doses used may have been too close to differentiate between intoxication and behavioral toxicity, 
as reflected by a steep response rate dose-effect function (no effect at 1.7 mg/kg vs nearly 
complete suppression at 3 mg/kg). In contrast, response rates were significantly increased by 3 
mg/kg Δ9-THC.     
Acute and long-lasting drug effects on rats: d 
Acute effects: Significant overall effect of ABPINACA on locomotor activity (low and high dose). 
Δ9-THC induced significant reduction only at high dose. In adolescent rats, AB-PINACA and Δ9-
THC produced locomotor suppression, anxiogenic effects (high dose) in the emergence test, 
increased audible vocalizations during handling (high dose) (supplementary measure of drug 
aversion) and inhibition of body weight gain (adult rats not affected); conditioned place aversion 
was not observed.  
 
Residual effects following 2 week washout period: d 
Novel object recognition test (% reduction): Significant overall effect of APINACA and Δ9-THC 
with inter-trial interval of 60 min but not at 2 min interval.  
 
Behavior/social interaction 19 days post-administration:  
Exploratory and social behavior scores did not reach statistical significance with AB-PINACA but 
total interaction scores were significantly reduced with Δ9-THC.  
 
Post-mortem plasma and cerebellum analyses: 
In plasma, levels of steroids, cytokines and ethanolamides remained unaffected by AB-PINACA 
and Δ9-THC. In the cerebellum, AB-PINACA induced significant reductions in anandamide, 
palmitoylethanolamide, and oleoylethanolamide concentrations. This was also observed with Δ9-
THC, which was also correlated with reduced 2-arachidonoylglycerol concentrations in the same 
tissue.  
Kevin et al.18  
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Microdialysis (nucleus accumbens): e 
AB-PINACA.  
5-HT increase: <200% (80 and 120 min, p<0.1 and 180 min, p<0.05). 
DA increase: >200% (180 min, p<0.01). 
 
Kim et al.19 
Conditioned place preference: f 
More time spent in drug-paired chamber (0.1 mg/kg AB-PINACA) 
 
Self-administration: f 
Results not reported / self-administration not observed? 
 
Behavioral sensitization: f 
Results not reported / sensitization not observed? 
 
Motor coordination: f 
Reduced rotarod performance compared to vehicle at 30 and 40 mg/kg.  
 
Behavioral tests: f 
AB-PINACA: Significant effects on Y-maze test at 10 mg/kg but not at 20 mg/kg. 
AB-PINACA: Reduced exploration of novel objects at 30 and 40 mg/kg. 
AB-PINACA: Reduced latency in passive avoidance test 30 and 40 mg/kg. 
 
Cha20 
a Ref3: Male Wistar rats; biotelemetry transmitters placed in the peritoneal cavity; drugs administered (i.p.) in an 
ascending dose sequence (0.1, 0.3, 1, 3 mg/kg) (10 mg/kg if required) at the same time of day; data for heart rate and 
body temperature gathered at 1000 Hz (15 or 30 min bins). Data were recorded for 6 h post-injection. For antagonist 
studies (30 min before test drug treatment), each cohort received injections of vehicle, CB1 antagonist (rimonabant, 3 
mg/kg), or CB2 antagonist (SR-144528, 3 mg/kg), followed by 3 mg/kg AB-PINACA. 
b Ref11: Male ICR mice; intraperitoneal injections of vehicle, Δ9-THC and AB-PINACA 30 min before test sessions; 
spontaneous activity measured for 10 min; tail-flick (radiant heat, intense light) and rectal temperature tested 30 min 
post-injection; ring immobility tested at 50 min post-injection. 
c Ref11: Male C57/BL6J mice; trained to respond on one of the two levers following intraperitoneal (i.p.) 
administration of 5.6 mg/kg Δ9-THC and to respond on the other lever following i.p. vehicle injection according to a 
fixed ratio 10 (FR10) schedule of food reinforcement, under which 10 consecutive responses on the correct (injection-
appropriate) lever resulted in delivery of a food pellet; 15 min daily training sessions were held until: a) the first 
completed FR10 was on correct lever; b) >80% of total responding on correct lever, and c) response rate >0.17 
responses/s. Additional mice were trained de novo on the nose poke response. 
d Ref18: Male albino Wistar rats; test drugs injected (i.p.) using a low and high dose regimen: AB-PINACA every 
second day (commencing post-natal day 31), first at 0.2 mg/kg on 6 days followed by 1 mg/kg on a further 6 days. Δ9-
THC-treated rats received equivalent doses of 6 × 1 mg/kg and 6 × 5 mg/kg. Behavioral assessment conducted over 
two phases: ‘on-drug’ phase (behavior measure 15 min post-injection) during repeated drug administration 
(adolescence, PNDs 31–55), and a ‘residual’ phase following a 2-week washout during adulthood (PNDs 69–94).    
e Ref19: Male Sprague–Dawley rats; microdialysis probe inserted into nucleus accumbens shell; six baseline samples 
collected following microdialysates every 20 min for 2 h. Test drug injected (i.p.) with increasing doses (0.3 at time 
zero, 1 at 60 min and 3 mg/kg at the 120 min point) and microdialysates were collected at 20 min intervals; analysis 
of DA, 5-HT, DOPAC, HVA and 5-HIAA done by LC-MS/MS.  
f Ref20: Male C57/BL6 mice used for conditioned place preference (0.01, 0.03, 0.1 mg/kg, i.p., unbiased method; 
animals not selected after pre-tracking), sensitization (change in locomotor activity across injections), motor function 
and memory tests; male Sprague-Dawley rats used for self-administration and microdialysis studies; Y-Maze tests, 
novel object recognition tests and passive avoidance tests were used to assess exploratory behavior/learning/memory. 
 
 
5. Toxicology 
During the evaluation of mouse tetrad effects (Table 2), AB-PINACA (30 mg/kg, i.p.) was 
observed to induce convulsions, flattened body posture (splayed limbs), and labored 
breathing in most mice within 1 minute. The mice recovered by the end of the tetrad 
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assays. During drug discrimination studies, a steep response rate dose-effect was 
observed.11 Chronic administration of AB-PINACA (Table 2) produced statistically 
significant inhibition of weight gain in adolescent rats. Total social interaction scores were 
not affected compared to vehicle although this was the case with Δ9-THC-treated rats.18 
Any other information related to acute and chronic preclinical toxicology could not be 
identified. 
 
6. Adverse Reactions in Humans 
Reports associated with the presence of AB-PINACA in drug products and biofluids is 
summarized in Table 3 below. The total number of cases reported in the scientific literature 
that make a specific causal link with AB-PINACA is small.  
 
Reported adverse drug reactions associated with a range of synthetic cannabinoids 
frequently include gastrointestinal (e.g. nausea/hyperemesis), neurological (e.g. 
hallucination, agitation, anxiety, paranoia, confusion, delusions, catatonia, lethargy, 
psychosis (including susceptible individuals)), cardiovascular (e.g. tachycardia, 
hypertension) and renal (e.g. acute kidney failure) features.21-23 
 
Table 3. Case reports associated with the involvement of AB-PINACA reported in the scientific literature. 
Year Cases Patient, age Comments (examples) Ref 
2013 1 M, 40 Death following a head on motor vehicle collision. Toxicology results of the 
opposing driver detected AB-PINACA and AB-FUBINACA in biological 
samples. 
DEA5, a 
2014 2 M, 19 
M, 37 
Two deaths involving AB-PINACA; cause of death in both cases deemed 
synthetic cannabinoid-related. 
DEA5 
2014 1 M, NR b Male presented with excited delirium; AB-PINACA detected on drug evidence. DEA5 
2014 2 M, 16 
F, 17 
Both experienced delirium after ingesting liquid drug form through hookah pen; 
AB-PINACA detected on drug evidence.   
DEA5 
2014 3 F, 15 
F, 15 
F, 17 
Patients suffered loss of consciousness and seizures following ingestion of a 
synthetic cannabinoid product. AB-PINACA and AB-CHMINACA detected on 
drug evidence. 
DEA5 
2014 4 NR, NR Four juveniles taken to emergency department following ingestion of e-liquid 
identified as “Cloud 9”; AB-PINACA detected in product. 
DEA5 
“Clusters of cases of adverse health effects or severe toxic effects and deaths associated with synthetic cannabinoid 
product use.” Analysis of clinical samples; details not reported. Locations: USA 
August 2014: 3 cases (AB-PINACA and AB-CHMINACA detected) (St. Louis, MO). 
August 2014: >44 cases (AM-2201 N-(3-chloropentyl) isomer, AB-PINACA, ADB-PINACA, UR-144 detected) 
(Manchester, NH).  
September 2014: 6 cases (AB-PINACA detected) (Westland, MI). 
December 2014-January 2015: >62 cases (MAB-CHMINACA, AB-PINACA, ADB-PINACA detected) (Beaumont, 
TX, USA). c 
June 2014: 2 cases (AB-FUBINACA, AB-PINACA detected) (Atlantic City, NJ). 
August 2014: 1 case and 1 death (THJ-2201, AB-PINACA detected) (Austin, TX). 
October 2014: 1 case (AB-PINACA detected) (Holdrege, NE). 
October 2014: 1 case and 1 death (AB-CHMINACA, AB-PINACA, ADB-PINACAMAB-CHMINACA detected) 
(Austin, TX). 
Trecki et 
al.24 
2015 25 Male 
95% 
Mean 
age 28; 
Range 
Review of 58 suspected impaired driving cases submitted to a laboratory in 
2014. Twenty-five cases involved AP-PINACA with blood concentrations 
ranging between 0.6-41.3 ng/mL (other synthetic cannabinoids detected in 5 
cases). Ten cases: Drug Recognition Expert exams: horizontal gaze nystagmus 
observed (n = 5 at low blood concentrations); lack of convergence (n = 7); low 
Peterson 
and 
Couper25 
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18-61 
 
blood pressure (<120/70 mm Hg) (n = 5); watery eyes and droopy eyelids 
observed n = unclear).  
 
Fifteen cases: Driving Under the Influence; erratic driving (n = 7); individual 
slumped over wheel or unconscious in the vehicle upon initial contact  (n = 4); 
drivers stopped in a roadway (n = 5); cases of collisions (n = 6). 
  
2015 1 F, 10 
months 
Ten months old female ingested less than half a cigarette; serum levels: 42 
ng/mL AB-PINACA and 345 ng/mL AB-PINACA N-pentanoic acid; within 90 
min of ED presentation, child stopped responding to verbal and physical stimuli 
and developed respiratory depression requiring intubation; patient was admitted 
and tested positive for influenza A and treated with oseltamivir, but aspiration 
pneumonia complicated her course; patient was intubated for 36 h and 
recovered. Serum values of the acid metabolite was detected at 232 ng/mL 
(serum) 12 h after presentation and 1.7 μg/mL levels in urine 16 h after 
presentation.  
 
Thornton 
et al.13 
2017 1 M, NR Motor vehicle collision case; details not reported (presumably from 2014); 
blood concentration of AB-PINACA = 0.04 ng/mL.  
Kaneko26 
a Details not reported; statements taken verbatim from reference. It is unclear whether there is an overlap with the case summary 
provided by Trecki et al.24 
b NR: not reported 
c “Substance identified on the basis of information about local law-enforcement seizures during the same period.” 
 
7. Dependence Potential 
A. Animal Studies 
No information available.  
B. Human Studies 
No information available.  
 
8. Abuse Potential 
A. Animal Studies 
As summarized in Tables 1 and 2 (Section 4C), AB-PINACA was shown to share 
some cannabinoid-like properties (e.g. binding to and activation of CB1 and CB2 
receptors). AB-PINACA was reported to induce (rimonabant-reversible) 
cannabinoid-like responses in the tetrad test battery. One drug discrimination study 
uncovered that AB-PINACA (more potently) substituted fully for Δ9-THC but the 
difference to Δ9-THC and some other synthetic cannabinoid receptor antagonists 
(e.g.27) was that full substitution was only achieved in two out of nine mice,11 which 
led to the suggestion that the dose needed to impair behavior/induce intoxication 
and the dose needed to produce behavioral toxicity might be very close or even 
indistinguishable (Table 2).11 These data suggest that AB-PINACA may have abuse 
liability and further studies are warranted to investigate this further. 
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B. Human Studies 
No information available.  
 
9. Therapeutic Applications and Extent of Therapeutic Use and 
Epidemiology of Medical Use 
AB-PINACA is not known to have any therapeutic applications. 
 
10. Listing on the WHO Model List of Essential Medicines 
AB-PINACA is not listed on the WHO Model List of Essential Medicines (20th List) or the 
WHO Model List of Essential Medicines for Children (6th List). 
 
11. Marketing Authorizations (as a Medicinal Product) 
AB-PINACA is not marketed as a medicine. 
 
12. Industrial Use 
AB-PINACA has no reported industrial use.  
 
13. Non-Medical Use, Abuse and Dependence 
Household or subpopulation surveys that specifically probe for prevalence of AB-PINACA 
could not be identified in the currently available literature. Epidemiological data, such as 
prevalence of use, abuse and dependence information, are not available specifically for 
AB-PINACA. However, heavy use of synthetic cannabinoid receptor agonists has been 
associated with problematic withdrawal symptoms (e.g.28, 29) and further research is needed 
to investigate the underlying mechanisms.  
 
14. Nature and Magnitude of Public Health Problems Related to Misuse, 
Abuse and Dependence 
The majority of available synthetic cannabinoid products (including those containing AB-
PINACA) is sold in the form of herbal mixtures, and designed for smoking purposes. It is 
common for retailers to purchase bulk quantities of the synthetic substance and to add the 
synthetic material to a variety of vegetable matter as the plant base. Products sold as herbal 
smoking mixtures frequently change in drug composition and quantity, often without 
indications on product labels, which results in challenges to unambiguously correlate 
harms to public health with a specific drug such as AB-PINACA. 
 
The consumption of these products might be attractive to a variety of users, such as regular 
users of cannabis and those who might wish to avoid drug-testing procedures resulting in 
positive cannabis findings. Ease of access, and perceived lack of control might equally be 
of interest to some users. The high potency associated with many synthetic cannabinoids 
carries the risk of accidental overdose and potentially severe adverse events but 
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information specific to AB-PINACA is limited. As highlighted in Section 6 (Table 3), the 
ingestion of AB-PINACA products has been implicated in cases of impaired driving and 
motor vehicle collisions,25, 26 which might add a public health dimension. Although not 
specific to AB-PINACA, there are indications that socially vulnerable and stigmatized drug 
users, for example found in homeless and prison populations, are increasingly associated 
with problematic use of synthetic cannabinoid receptor agonist products.30-33  
 
15. Licit Production, Consumption and International Trade 
AB-PINACA is available as standard reference material and produced for scientific 
research by a number of commercial suppliers. Other uses could not be identified. 
 
16. Illicit Manufacture and Traffic and Related Information 
Reports have been received from the European Early-Warning System on new 
psychoactive substances that AB-PINACA (first detected in 2013) was encountered in 
seizures and collected specimen (herbal mixtures or powders) in Sweden, Hungary, 
Turkey, Germany, France, Croatia, Latvia, Bulgaria, Slovakia, Spain and Slovenia.34  
 
AB-PINACA detections started to appear in United States of America (USA) in 2013. The 
National Forensic Laboratory Information System (NFLIS), which is dedicated to the 
collection of drug cases submitted by State and local laboratories in the USA, registered a 
particular increase in 2014 (Table 4), which has also been exemplified in the fact that 
ABPINACA did not feature in the NFLIS special report covering the 2010-2013 time 
period.35 In 2014, AB-PINACA and AB-FUBINACA were the most commonly reported 
synthetic cannabinoid receptor agonists but this figure dropped since 2015, which reflected 
the emergence of new replacements,36, 37 presumably as a consequence of issuing an order 
to temporarily schedule AB-PINACA into Schedule I of the Controlled Substances Act.38, 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detections of AB-PINACA have also been reported to UNODC’s Early Warning Advisory 
on New Psychoactive Substances.46 AB-PINACA was reported by one country (Japan47) in 
2012, 19 countries in 2013, 21 countries in 2014, 18 countries in 2015 and 7 countries in 
2016 (as of 08 August 2017).  
Table 4. Number of reports received by the U.S. National Forensic Laboratory 
Information System (NFLIS) related to detections of AB-PINACA in law 
enforcement operations. 
Year a Numbers XLR-11 MDMA Meth b Ref 
2013 (MY) -- 11,273 2,423 100,045 NFLIS40 
2013 (AR) 965 19,243 4,798 206,784 NFLIS41 
2014 (MY) c 2,168 6,316 2,224 117,318 NFLIS42 
2014 (AR) 4,954 11,001 4,902 236,175 NFLIS43 
2015 (MY) 1,893 3,769 2,421 133,374 NFLIS44 
2015 (AR) 2,493 6,973 5,188 277,823 NFLIS45 
2016 (MY) 243 1,409 2,901 155,535 NFLIS37 
a MY: mid-year report (January to June); AR: annual report (January to December). 
b Meth: methamphetamine. 
c Revised March 2016. 
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17. Current International Controls and Their Impact 
AB-PINACA is not controlled under the 1961, 1971 or 1988 United Nations Conventions. 
 
18. Current and Past National Controls 
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation on 
the Scheduling of the Substance 
Not applicable. 
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Annex 1: Report on WHO Questionnaire for Review of Psychoactive 
Substances for the 39th ECDD: Evaluation of AB-PINACA 
 
Please refer to separate Annex 1 document published on ECDD website 
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Annex 2: Studies associated with the detection and chemical analysis 
of AB-PINACA (amongst other substances) published in the scientific 
literature.  
 
 
Techniques a Comment Reference 
Melting point, 1H-NMR, GC-
MS 
Characterization of reference material. SWGDRUG1 
LC-UV/DAD, LC-MS, NMR, 
DART-TOF-MS 
Identification in samples purchased on the Internet in July 2012 in Japan. Uchiyama et al.2 
Not reported Review of seized products in South Korea. Chung et al.3, 4 
1H-NMR Analysis of reference material. Huang et al.5 
LC-QqQ-MS/MS In vitro metabolism studies using human liver microsomes. Takayama et al.6 
NMR, ESI-MS Synthesis and use in pharmacological investigations.  Banister et al.7 
LC-QTOF-MS/MS Analysis of urine samples. Labutin et al.8  
LC-QqQ-MS/MS Analysis of blood samples from suspected impaired driving cases. Peterson et al.9 
LC-QTOF-MS/MS Method development and analysis of authentic urine samples. Scheidweiler et al.10 
LC-Q-Orbitrap-MS/MS In vitro metabolism studies using human liver microsomes and recombinant 
carboxylesterases. 
Thomsen et al.11 
LC-QTOF-MS Serum analysis of accidental exposure in 10-moth old girl.  Thornton et al.12, 13 
Not reported Summary of cases related to acute intoxications.  Trecki et al.14 
LC-QTOF-MS/MS Analysis of urine samples obtained from mice. Wiley et al.15 
LC-QqQ-TOF-MS In vitro metabolism studies using human liver microsomes, human 
hepatocytes and analysis of authentic urine samples. 
Wohlfarth et al.16 
GC-MS, LC-TOF-MS Characterization of reference material. Akamatsu et al.17 
Cyclic and differential pulse 
voltammetry, GC-MS, LC-
QTOF-MS 
Electrochemical characterization of reference material. Dronova et al.18 
Immunodetection Antibody binding characteristics of reference material Fitzgerald et al.19 
Melting point, TLC, NMR, ESI-
HR-MS; IR, UV, GC-MS 
Synthesis and characterization for pharmacological studies. Longworth et al.20 
LC-QTOF-MS/MS Analysis of collected samples. Bijlsma et al.21 
LC-QqQ-MS/MS Stability study in whole blood. Fort et al.22 
Not reported Review of impaired driving cases.  Kaneko23 
LC-QTRAP-MS/MS Detection in urine samples obtained from fatalities. Minakata et al.24 
LC-Q-Orbitrap-MS/MS In vitro metabolism studies using various human liver preparations and 
comparison with authentic urine specimen.  
Richter et al.25 
LC-QqQ-MS/MS Method development and application to analysis of blood samples. Tynon et al.26 
   
a NMR: nuclear magnetic resonance spectroscopy; GC: gas chromatography; MS: mass spectrometry; ATR-FTIR: attenuated total 
reflection Fourier transform infrared spectroscopy; LC: liquid chromatography (various forms); UV: ultraviolet; DAD: diode array 
detector; DART: direct analysis in real time; TOF: time-of-flight; QqQ: triple quadrupole; MS/MS: tandem mass spectrometry; ESI: 
electrospray ionization; Q: quadrupole; QTRAP: quadrupole-linear ion trap; TLC: thin-layer chromatography; HR: high resolution.  
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